Drug Profile
Aspirin/niacin
Alternative Names: CER-627Latest Information Update: 11 Sep 2019
Price :
$50
*
At a glance
- Originator Cerenis Therapeutics
- Class Nicotinic acids; Salicylic acids
- Mechanism of Action Cyclooxygenase inhibitors; GPR109A receptor agonists; GPR109B receptor agonists; Nitric oxide stimulants; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Dyslipidaemias
Most Recent Events
- 24 Jun 2010 Phase-I clinical trials in Dyslipidaemias in USA (PO)
- 24 Jun 2010 Cerenis Therapeutics completes two phase I trials in volunteers in USA